SCHEMBL8914547

SCHEMBL8914547

O=C1/C=C\CCCCCCO1

nearest known ligand 0.65

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.65
CA9 Q16790 3/20 0.65
ALDH1A1 P00352 1/20 0.41
GLS O94925 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31344151 1.00 CA1 (0.65) CA1CA9ALDH1A1GLS
SCHEMBL29516478 1.00 CA1 (0.65) CA1CA9ALDH1A1GLS
SCHEMBL3823000 1.00 CA1 (0.65) CA1CA9ALDH1A1GLS
SCHEMBL2840942 1.00 CA1 (0.65) CA1CA9ALDH1A1GLS
SCHEMBL756918 1.00 CA1 (0.65) CA1CA9ALDH1A1GLS
SCHEMBL985747 1.00 CA1 (0.65) CA1CA9ALDH1A1GLS
SCHEMBL294711 1.00 CA1 (0.65) CA1CA9ALDH1A1GLS
SCHEMBL20241693 1.00 CA1 (0.65) CA1CA9ALDH1A1GLS
SCHEMBL20241380 1.00 CA1 (0.65) CA1CA9ALDH1A1GLS
SCHEMBL28365908 1.00 CA1 (0.65) CA1CA9ALDH1A1GLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102399209-B Nonenolactone compound, and its preparation and application SHANGHAI LAIYI BIOMEDICAL RES AND DEV CT CO LTD 2014-07-23 CN claimed
CN-102399209-A Nonenolactone compound, and its preparation and application SHANGHAI LAIYI BIOMEDICAL RES AND DEV CT CO LTD 2012-04-04 CN claimed
US-20260041094-A1 Compositions Comprising an Antimicrobial Boosting Agent SYMRISE AG (DE) 2026-02-12 US disclosed
EP-4110276-B1 COMPOSITIONS COMPRISING ALKANEDIOLS SYMRISE AG (DE) 2026-01-28 EP disclosed
CN-115916945-B Beer flavor beverage 三得利控股株式会社 2025-03-21 CN disclosed
WO-2025031562-A1 MYCOSPORINE-LIKE AMINO ACID ANALOGUE COMPOUNDS AND USE THEREOF SYMRISE AG (DE) 2025-02-13 WO disclosed
US-12193441-B2 Antimicrobial mixtures comprising at least one hydroxyphenone derivative SYMRISE AG (DE) 2025-01-14 US disclosed
EP-4477264-A2 COMPOSITIONS COMPRISING ONE OR MORE (BIO)-ALKANEDIOLS WITH ACTIVE INGREDIENTS Symrise AG (DE) 2024-12-18 EP disclosed
US-20240373845-A1 ANTIMICROBIAL MIXTURES COMPRISING AT LEAST ONE HYDROXYPHENONE DERIVATIVE SYMRISE AG (DE) 2024-11-14 US disclosed
EP-4450128-A2 ANTIMICROBIAL COMPOSITIONS Symrise AG (DE) 2024-10-23 EP disclosed
CN-112702914-B Antimicrobial mixtures containing at least one hydroxyacetophenone derivative 西姆莱斯股份公司 2024-01-30 CN disclosed
CN-116615172-A Composition comprising a natural polymer and one or more (bio) alkanediols 西姆莱斯股份公司 2023-08-18 CN disclosed
US-20220168198-A1 AN ANTIMICROBIAL MIXTURE SYMRISE AG (DE) 2022-06-02 US disclosed
CN-109475120-B Antimicrobial compositions 西姆莱斯股份公司 2022-03-29 CN disclosed
US-20220031590-A1 ORAL CARE COMPOSITION SYMRISE AG (DE) 2022-02-03 US disclosed
CN-102399209-B Nonenolactone compound, and its preparation and application SHANGHAI LAIYI BIOMEDICAL RES AND DEV CT CO LTD 2014-07-23 CN disclosed
CN-102399209-A Nonenolactone compound, and its preparation and application SHANGHAI LAIYI BIOMEDICAL RES AND DEV CT CO LTD 2012-04-04 CN disclosed
US-5646022-A Process for the production of gamma nonalactones in natural form SAN GIORGIO FLAVORS S.P.A. (IT) 1997-07-08 US disclosed
EP-0694615-A2 Process for the preparation of gamma-nonalactones in native form PERNOD-RICARD (FR) 1996-01-31 EP disclosed
EP-0687673-A1 Oxazole derivatives as antitumoral agents PHARMA MAR, S.A. (ES) 1995-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220031590-A1 ORAL CARE COMPOSITION TAS2R39, NOX5, F9 CA1 3968/4885CA9 665/4885ALDH1A1 3698/4885
US-20240373845-A1 ANTIMICROBIAL MIXTURES COMPRISING AT LEAST ONE HYDROXYPHENONE DERIVATIVE HPD, GRHPR, ALDH7A1 CA1 1926/4885CA9 3265/4885ALDH1A1 66/4885
US-20260041094-A1 Compositions Comprising an Antimicrobial Boosting Agent TLR7, MYC, ERG28 CA1 4875/4885CA9 4679/4885ALDH1A1 4611/4885
US-12193441-B2 Antimicrobial mixtures comprising at least one hydroxyphenone derivative HOGA1, GNPAT, CLPP CA1 4727/4885CA9 4770/4885ALDH1A1 43/4885
US-20220168198-A1 AN ANTIMICROBIAL MIXTURE TMSB10, FHIT, EBP CA1 4855/4885CA9 4834/4885ALDH1A1 3016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.